Citizens Jmp Cuts Compass Therapeutics (NASDAQ:CMPX) Price Target to $4.00

Compass Therapeutics (NASDAQ:CMPX) had its target price reduced by research analysts at Citizens Jmp to $4.00 in a research report issued on Wednesday, Benzinga reports. The brokerage presently has a “market outperform” rating on the stock. Citizens Jmp’s price objective indicates a potential upside of 222.58% from the stock’s current price.

Several other equities analysts also recently issued reports on the stock. Wall Street Zen downgraded shares of Compass Therapeutics from a “sell” rating to a “strong sell” rating in a report on Saturday, August 8th. Citigroup reissued a “market outperform” rating on shares of Compass Therapeutics in a research note on Wednesday. Wedbush set a $4.00 price target on shares of Compass Therapeutics in a research report on Wednesday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Compass Therapeutics in a research note on Friday, July 17th. Finally, Guggenheim lowered their price objective on Compass Therapeutics to $4.00 and set a “buy” rating on the stock in a report on Wednesday. One research analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Compass Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $10.21.

Compass Therapeutics Stock Down 31.9%

Compass Therapeutics stock opened at $1.24 on Wednesday. Compass Therapeutics has a 52 week low of $1.15 and a 52 week high of $6.88. The company has a market capitalization of $223.31 million, a price-to-earnings ratio of -3.10 and a beta of 0.95. The stock has a 50-day moving average price of $2.14 and a 200 day moving average price of $2.96.

Compass Therapeutics (NASDAQ:CMPX) last issued its earnings results on Thursday, August 6th. The company reported ($0.13) EPS for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.02). Research analysts anticipate that Compass Therapeutics will post -0.47 EPS for the current fiscal year.

Institutional Trading of Compass Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of CMPX. Parallel Advisors LLC purchased a new position in Compass Therapeutics in the 1st quarter valued at approximately $28,000. PNC Financial Services Group Inc. increased its position in shares of Compass Therapeutics by 2,572.6% during the first quarter. PNC Financial Services Group Inc. now owns 11,038 shares of the company’s stock worth $58,000 after acquiring an additional 10,625 shares during the period. HB Wealth Management LLC purchased a new stake in shares of Compass Therapeutics during the second quarter worth $29,000. State of Wyoming acquired a new stake in shares of Compass Therapeutics in the second quarter valued at $31,000. Finally, Pictet Asset Management Holding SA acquired a new stake in shares of Compass Therapeutics in the first quarter valued at $76,000. 68.43% of the stock is owned by institutional investors and hedge funds.

Compass Therapeutics Company Profile

Compass Therapeutics, Inc is a clinical-stage biotechnology company focused on developing antibody-based medicines designed to activate and direct the immune system against cancer and other serious diseases. The company’s research is centered on immuno-oncology, with the goal of creating therapies that can stimulate antitumor immune responses and improve outcomes for patients.

Compass Therapeutics has developed a pipeline of proprietary antibody therapeutics, including CTX-471, an investigational monoclonal antibody intended to activate CD137, an immune-stimulatory receptor found on certain immune cells.